

February 15, 2022
Sawai Pharmaceutical Co., Ltd.

Sawai Receives Approvals for Seven Generic Drugs with 14 Strengths

Osaka, Japan – February 15, 2022 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) received approvals by the Ministry of Health, Labour and Welfare for seven generic drugs with 14 strengths. The five compounds marked with an asterisk below are approved for the first time as generics.

The list of approved products:

1. Tolvaptan Granules

Generic name:	Tolvaptan*	Strengths:	Granules: 1%
Brand products:	Samsca [®] granules 1%		

2. Febuxostat Tablets, OD Tablets

Generic name:	Febuxostat*	Strengths:	Tablets: 10mg, 20mg, 40mg OD Tablets: 10mg, 20mg, 40mg
Brand products:	Feburic [®] Tablets 10mg, 20mg, 40mg		

3. Teriparatide Injection

Generic name:	Teriparatide Acetate	Strengths:	Injection: 56.5µg
Brand products:	Teribone [®] Injection 56.5µg		

4. Dasatinib Tablets

Generic name:	Dasatinib Hydrate*	Strengths:	Tablets: 20mg, 50mg
Brand products:	SPRYCEL [®] Tablets 20mg, 50mg		

5. Azacitidine for Injection

Generic name:	Azacitidine*	Strengths:	Injection: 100mg
Brand products:	Vidaza [®] for Injection 100mg		

6. Aripiprazole Tablets, Oral Solution

Generic name:	Aripiprazole	Strengths:	Tablets: 1mg Oral Solution: 1mg
Brand products:	ABILIFY [®] tablets 1mg, ABILIFY [®] oral solution 0.1%		

7. Omega-3-Acid Ethyl Esters Granular Capsules

Generic name:	Omega-3-acid ethyl esters*	Strengths:	Granular Capsules: 2g
Brand products:	LOTRIGA [®] 2g		

The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.

◆ Contact Information ◆

Public Relations Office, Sawai Pharmaceutical Co., Ltd.

E-mail : koho@sawai.co.jp